아데노신 디아미나제 결핍형 중증 복합 면역결핍증(ADA-SCID) 시장 규모, 점유율, 성장 분석 : 치료 유형별, 치료 단계별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Adenosine Deaminase Severe Combined Immunodeficiency Market size was valued at USD 284.1 Million in 2024 and is poised to grow from USD 300.63 Million in 2025 to USD 7.96 Million by 2033, growing at a CAGR of 5.82% during the forecast period (2026-2033).

The global market for Adenosine Deaminase deficient Severe Combined Immunodeficiency (ADA-SCID) is centered around innovative therapies focused on replacing or correcting the missing enzyme, crucial for preventing life-threatening infections in vulnerable infants. The rarity of this condition, coupled with the significant treatment costs, has led to government and insurer support for advanced therapies. The evolution of this market has been marked by the emergence of enzyme-replacement therapies and groundbreaking gene-editing technologies, including CRISPR, which facilitate durable immune reconstitution with fewer treatments. As the pipeline expands, automation in gene editing is enhancing production efficiency, lowering costs, and enabling smaller biotech firms to participate. This trend, supported by real-world data showcasing effective outcomes, is drawing investors and expanding patient access globally, ultimately driving market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Adenosine Deaminase Severe Combined Immunodeficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Segments Analysis

Global adenosine deaminase severe combined immunodeficiency market is segmented by therapy type, treatment stage, route of administration, end user, distribution channel and region. Based on therapy type, the market is segmented into Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplantation (HSCT) and Gene Therapy. Based on treatment stage, the market is segmented into First-Line Treatment and Subsequent/Salvage Treatment. Based on route of administration, the market is segmented into Intravenous (IV) and Intramuscular (IM). Based on end user, the market is segmented into Hospitals, Specialty Clinics and Transplant Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Adenosine Deaminase Severe Combined Immunodeficiency Market

The market for adenosine deaminase severe combined immunodeficiency is significantly driven by advancements in gene-based therapies, which offer improved safety profiles, more efficient manufacturing processes, and greater regulatory acceptance. These factors help diminish obstacles for both clinicians and patients, thereby boosting confidence among healthcare providers and prompting investments in specialized facilities. This dynamic accelerates patient enrollment in clinical programs, ultimately broadening the market's reach and fostering stable growth across various regions. Additionally, it encourages collaboration among academic institutions, biotechnology companies, and patient advocacy organizations, creating a supportive ecosystem that enhances overall market momentum.

Restraints in the Global Adenosine Deaminase Severe Combined Immunodeficiency Market

The global market for adenosine deaminase severe combined immunodeficiency therapies faces significant challenges primarily due to the complexities involved in gene-based treatments. The manufacturing processes, specialized delivery systems, and the need for extensive clinical monitoring contribute to high costs that complicate reimbursement efforts. Payers frequently demand in-depth cost-effectiveness evaluations, which can result in delayed or limited reimbursement decisions, thereby restricting patient access to care and hindering wider adoption among healthcare professionals. These financial challenges create barriers that reduce the potentially addressed patient population and slow down investment in necessary ancillary services. Additionally, restrictions in funding programs often limit participation in clinical trials, further inhibiting market progress.

Market Trends of the Global Adenosine Deaminase Severe Combined Immunodeficiency Market

The Global Adenosine Deaminase Severe Combined Immunodeficiency market is witnessing a transformative shift driven by innovative gene therapy modalities. Cutting-edge gene editing technologies, including CRISPR-Cas9 and base editing, are revolutionizing treatment approaches for adenosine deaminase deficiency, offering unprecedented precision in rectifying pathogenic mutations while maintaining immune system integrity. This wave of advancement, bolstered by collaborative research initiatives, is yielding promising results in preclinical studies and early-stage trials, highlighting favorable safety profiles. Increased investment from biotech companies is expanding the pipeline of innovative therapeutic candidates, suggesting a significant evolution in long-term disease management for affected infants and their families beyond traditional enzyme replacement therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Enzyme Replacement Therapy (ERT)
• Hematopoietic Stem Cell Transplantation (HSCT)
• Gene Therapy

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by Treatment Stage & CAGR (2026-2033)

• Market Overview
• First-Line Treatment
• Subsequent/Salvage Treatment

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous (IV)
• Intramuscular (IM)

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Transplant Centers

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Adenosine Deaminase Severe Combined Immunodeficiency Market Size & CAGR (2026-2033)

• North America (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Treatment Stage, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Leadiant Biosciences Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mustang Bio Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rocket Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzon Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations